Adding lamotrigine to valproate: Incidence of rash and other adverse effects

Epilepsia

Volumn 40, Issue 8, 1999, Pages 1135-1140

  Faught, Edward ^a,h   Morris, George ^b   Jacobson, Mercedes ^c   French, Jacqueline ^d   Harden, Cynthia ^e   Montouris, Georgia ^f   Rosenfeld, William ^g  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

^c DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e Department of Obstetrics Gynecology   (United States)

^f Epi Care Center   (United States)

^g ST LUKE S HOSPITAL   (United States)

^h UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Allergies; Epilepsy; Lamotrigine; Rash; Valproate

Indexed keywords

LAMOTRIGINE; VALPROIC ACID;

ALLERGY; ARTICLE; BLOOD TOXICITY; DISEASE CLASSIFICATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; EPILEPSY; FEMALE; FOLLOW UP; GASTROINTESTINAL TOXICITY; HUMAN; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; NEUROTOXICITY; PRIORITY JOURNAL; RASH;

EID: 0032773248     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1528-1157.1999.tb00831.x     Document Type: Article

References (15)

1. Besag FMC, Wallace SJ, Dulac O, Alving J, Spencer SC, Hosking G. Lamotrigine for the treatment of epilepsy in childhood. J Pediatr 1995:127:991-7.
2. Li LM, Russo M, O'Donoghur MF, Duncan JS, Sander JWAS. Allergic skin rash with lamotrigine and concomitant valproate therapy. Arq Neuropsiquiatr 1996;54:47-9.
3. Burroughs Wellcome Company. Lamictal package insert. December 1994.
4. Schlumberger E, Chavez F, Palacios L, Rey E, Pajet N, Dulac O. Lamotrigine in treatment of 120 children with epilepsy. Epilepsia 1994;35:359-67.
5. Betts T, Goodwin G, Withers RM, Yuen AWC. Human safety of lamotrigine. Epilepsia 1991;32(suppl 2):517-21.
6. Chadwick D, Shaw MDM, Fay P, Rawlins MD, Turnbull DM. Serum anticonvulsant concentration and the risk of drug-induced skin eruptions. J Neurol Neurosurg Psychiatry 1984;47:642-4.
7. Betts T. Clinical use of lamotrigine. Seizure 1992;1:3-6.
8. Brodie MJ. Lamotrigine. Lancet 1992;339:1397-400.
9. Richens A. Safety of lamotrigine. Epilepsia 1994;35(suppl 5):537-40.
10. Matsuo F, Bergen D, Faught E, et al. Placebo-controlled study of the efficacy and safety of lamotrigine in patients with partial seizures. Neurology 1993;43:2284-91.
11. Messenheimer J, Ramsay RE, Willmore LJ, et al. Lamotrigine therapy for partial seizures: a multicenter, placebo-controlled, double-blind, cross-over trial. Epilepsia 1994;35:113-21.
12. Jawad S, Richens A, Goodwin G, Yuen WC. Controlled trial of lamotrigine (Lamictal) for refractory partial seizures. Epilepsia 1989;30:356-63.
13. Pellock JM. The clinical efficacy of lamotrigine as an antiepileptic drug. Neurology 1994;44:29-35.
14. Dooley J, Camfield P, Gordon K, Camfield C, Wirrell E, Smith E. Lamotrigine-induced rash in children. Neurology 1996;46:240-2.
15. Brodie MJ, Richens A, Yuen AWC. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet 1995;345:476-9.